May 4 Regeneron Pharmaceuticals Inc
reported a 37.2 percent increase in first-quarter profit, driven
by higher demand for its flagship eye drug Eylea.
The company said net income rose to $248.9 million, or $2.16
per share, in the quarter ended March 31, from $181.4 million,
or $1.59 per share, a year earlier.
Total revenue, which also includes collaboration revenue
from partners Sanofi SA and Bayer AG, rose
nearly 10 percent to $1.32 billion.
U.S. sales of Eylea rose 9 percent in the latest quarter.
Eylea accounted for about 68 percent of the U.S.
biotechnology company's total revenue in 2016.
(Reporting by Divya Grover in Bengaluru; Editing by Savio